LONG BEACH, CA - March 11, 2026 - PRESSADVANTAGE - Moment of Clarity has published a new educational resource detailing ...
Moment of Clarity has published a comprehensive new resource on its website addressing insurance coverage for transcranial ...
TMS is a well-established therapy for treatment-resistant depression. Large clinical studies show that it significantly reduces symptoms in 60 to 70% of patients, and 25 to 35% achieve remission. Most ...
Soterix Medical Inc., the global leader in non-invasive stimulation and integrated brain monitoring technologies, announced today clearance from the U.S. Food & Drug Administration (FDA) for the SPRY ...
TMS uses electromagnetic induction to stimulate neurons, similar to how a wireless charger transfers energy. The FDA has cleared TMS for Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder ...
Moment of Clarity has released a new educational resource providing a detailed examination of the “benefits and limitations of Transcranial Magnetic Stimulation (TMS) therapy“. The article, now ...
Published results have shown 87% clinical response to non-invasive Transcranial Magnetic Stimulation with neuroplastic medications.Clinical ...
CHEYENNE – Cheyenne Regional Medical Center is expanding access to behavioral health care with the addition of NeuroStar Transcranial Magnetic Stimulation therapy, recently cleared by the U.S. Food an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results